Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Authors:
- Eric BouffetEBEric Bouffet
- Valérie LaroucheVLValérie Larouche
- Brittany B. CampbellBCBrittany B. Campbell
- Daniele MericoDMDaniele Merico
- Richard de BorjaRBRichard de Borja
- Melyssa AronsonMAMelyssa Aronson
- Carol DurnoCDCarol Durno
- Joerg KruegerJKJoerg Krueger
- Vanja CabricVCVanja Cabric
- Vijay RamaswamyVijay Ramaswamy
- Nataliya ZhukovaNZNataliya Zhukova
- Gary MasonGMGary Mason
Top Cited Papers
- 1 July 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (19) , 2206-2211
Abstract
Purpose: Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) is a highly penetrant childhood cancer syndrome often resulting in GBM characterized by a high mutational burden. Evidence suggests that high mutation and neoantigen loads are associated with response to immune checkpoint inhibition. Patients and Methods: We performed exome sequencing and neoantigen prediction on 37 bMMRD cancers and compared them with childhood and adult brain neoplasms. Neoantigen prediction bMMRD GBM was compared with responsive adult cancers from multiple tissues. Two siblings with recurrent multifocal bMMRD GBM were treated with the immune checkpoint inhibitor nivolumab. Results: All malignant tumors (n = 32) were hypermutant. Although bMMRD brain tumors had the highest mutational load because of secondary polymerase mutations (mean, 17,740 ± standard deviation, 7,703), all other high-grade tumors were hypermutant (mean, 1,589 ± standard deviation, 1,043), similar to other cancers that responded favorably to immune checkpoint inhibitors. bMMRD GBM had a significantly higher mutational load than sporadic pediatric and adult gliomas and all other brain tumors (P < .001). bMMRD GBM harbored mean neoantigen loads seven to 16 times higher than those in immunoresponsive melanomas, lung cancers, or microsatellite-unstable GI cancers (P < .001). On the basis of these preclinical data, we treated two bMMRD siblings with recurrent multifocal GBM with the anti–programmed death-1 inhibitor nivolumab, which resulted in clinically significant responses and a profound radiologic response. Conclusion: This report of initial and durable responses of recurrent GBM to immune checkpoint inhibition may have implications for GBM in general and other hypermutant cancers arising from primary (genetic predisposition) or secondary MMRD.Keywords
This publication has 27 references indexed in Scilit:
- Germline Mutations in Predisposition Genes in Pediatric CancerNew England Journal of Medicine, 2015
- The odds of immunotherapy successScience, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancersNature Genetics, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘Care for CMMRD’ (C4CMMRD)Journal of Medical Genetics, 2014
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortiumEuropean Journal of Cancer, 2014
- Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow‐up of a kindredPediatric Blood & Cancer, 2011